依普利酮去哪里可以买到？

(Inspra) is produced by Novartis in Switzerland and is the first selective aldosterone receptor antagonist. Studies have found that in vitro, the affinity of eplerenone for aldosterone receptors is 1/10 to 1/20 of spironolactone, but its efficacy in vivo is 50% to 75% of spironolactone. The 17α thioacetyl group of spironolactone is replaced by a methyl ester group, which significantly improves the selectivity of eplerenone for aldosterone receptors.

Eplerenone was approved for clinical use by the State Food and Drug Administration in 2002 and has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. Eplerenone (Inspra) is safe and well-tolerated, making it a good alternative to spironolactone. Brings new options to the treatment of cardiovascular disease.

Eplerenone is not currently on the market in my country, so it is not sold in domestic pharmacies or hospitals yet. Since it has not yet been launched in China, where to buy eplerenone (Inspra) has become a matter of great concern. It is understood that the Indian version of eplerenone (Inspra) is currently more popular on the market, produced by India's Lupine Pharmaceuticals, and the price is relatively low.

The Indian version of eplerenone has a specification of 50mg*100 tablets and a price of around $500. There are usually two ways to purchase. One is for patients or family members to go abroad to purchase in person. There is no need to worry about buying counterfeit medicines in regular pharmacies in India. However, many patients complain that it is inconvenient to go abroad due to language barriers and long distances. The second is to contact a formal overseas medical consulting service company in China. Medical Companion Travel is a company specializing in transnational medical consulting. If you have purchasing needs, you can consult Medical Companion Travel Service.

The above is the introduction to the purchase channels of (Inspra), I hope it will be helpful to you.

Recommended related hot articles: /newsDetail/72869.html